

DAFTAR PUSTAKA

- A, Morissan M. 2014. Metode Penelitian Survei. Jakarta: Kencana
- Acilu, M. G. De *et al.* (2015) ‘The Role of Omega-3 Polyunsaturated Fatty Acids in the Treatment of Patients with Acute Respiratory Distress Syndrome : A Clinical Review’, *BioMed Research International*, 2015.
- Agarwal, N. and Dewan, P. (2016) ‘Writing a review article: Making sense of the jumble’, *Indian Pediatrics*, 53(8), pp. 715–720. doi: 10.1007/s13312-016-0915-z.
- Alexaki, V. I. and Henneicke, H. (2021) ‘The Role of Glucocorticoids in the Management of COVID-19’, *Hormone and Metabolic Research*, 53(1), pp. 9–15. doi: 10.1055/a-1300-2550.
- Arabi, Y. M. *et al.* (2018) ‘Corticosteroid therapy for critically ill patients with middle east respiratory syndrome’, *American Journal of Respiratory and Critical Care Medicine*, 197(6), pp. 757–767. doi: 10.1164/rccm.201706-1172OC.
- Aromataris, E. and Pearson, A. (2014) ‘The systematic review: An overview’, *American Journal of Nursing*, 114(3), pp. 53–58. doi: 10.1097/01.NAJ.0000444496.24228.2c.
- Arzinda, S. *et al.* (2020) ‘Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease’, *Annals of Medicine and Surgery*, 60(November), pp. 413–416. doi: 10.1016/j.amsu.2020.11.027.
- Ashbaugh, D. G. *et al.* (1967) ‘Acute respiratory distress in adults.’, *The Lancet*, 106(3), pp. 497–501. doi: 10.1148/106.3.497.
- Bahl, A., Johnson, S. and Chen, N. W. (2021) ‘Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients’, *Internal and Emergency Medicine*, 16(6), pp. 1593–1603. doi: 10.1007/s11739-021-02655-6.
- Bakhtiar, A. and Maranatha, R. A. (2018) ‘Acute Respiratory Distress Syndrome’, *Jurnal Respirasi*, 4(4), pp. 500–512.
- Bernard, G. R. *et al.* (1994) ‘The American-European Consensus Conference on ARDS: Definitions , Mechanisms , Relevant Outcomes , and Clinical Trial Coordination’, *Critical Care Medicine*, 149, pp. 818–824.
- Bhaskar, S. *et al.* (2020) ‘Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper’, *Frontiers in Immunology*, 11(July). doi: 10.3389/fimmu.2020.01648.
- Boglione, L. *et al.* (2021) ‘Role of the early short-course corticosteroids

- treatment in ARDS caused by COVID-19: A single-center, retrospective analysis', *Advances in Medical Sciences*, 66(2), pp. 262–268. doi: 10.1016/j.advms.2021.04.002.
- Bohn, M. K. *et al.* (2020) 'Pathophysiology of COVID-19: Mechanisms underlying disease severity and progression', *Physiology*, 35(5), pp. 288–301. doi: 10.1152/physiol.00019.2020.
- Burhan, E. *et al.* (2020) 'PEDOMAN TATALAKSANA COVID-19', *PDPI, PERKI, PAPDI, PERDATIN, IDAI*, pp. 1–57.
- Chen, N. *et al.* (2020) 'Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study', *The Lancet*, 395(10223), pp. 507–513. doi: 10.1016/S0140-6736(20)30211-7.
- Chen, W. *et al.* (2020) 'Plasma CRP level is positively associated with the severity of COVID - 19', *Annals of Clinical Microbiology and Antimicrobials*, 19(18), pp. 1–7. doi: 10.1186/s12941-020-00362-2.
- Chrousos, G. P. (2018) 'Adrenocorticosteroids & Adrenocortical Antagonists', in Katzung, B. G. (ed.) *Basic and clinical pharmacology*. 14th edn. new york: McGraw-Hill Education, pp. 703–719. doi: 10.1016/bs.seda.2019.07.006.
- Confalonieri, M., Salton, F. and Fabiano, F. (2017) 'Acute respiratory distress syndrome', *European Respiratory Review*, 26(144). doi: 10.1183/16000617.0116-2016.
- Cui, Z. *et al.* (2021) 'Early and significant reduction in C-reactive protein levels after Corticosteroid therapy is associated with reduced mortality in patients with COVID-19', *Journal of Hospital Medicine*, 16(3), pp. 142–148. doi: 10.12788/jhm.3560.
- Fanelli, V. *et al.* (2013) 'Review Article Acute respiratory distress syndrome : new definition , current and future therapeutic options', *journal of Thoracic Disease*, 5(3). doi: 10.3978/j.issn.2072-1439.2013.04.05.
- Ferguson, N. D. *et al.* (2012) 'The Berlin definition of ARDS: An expanded rationale, justification, and supplementary material', *Intensive Care Medicine*, 38(10), pp. 1573–1582. doi: 10.1007/s00134-012-2682-1.
- Garg, R. (2016) 'Methodology for research I', *Indian Journal of Anaesthesia*, 60(9), pp. 640–645. doi: 10.4103/0019-5049.190619.
- Gibson, P. G., Qin, L. and Puah, S. H. (2020) 'COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS', *Medical Journal of Australia*, 213(2), pp. 54-56.e1. doi: 10.5694/mja2.50674.
- Goodwin, J. S. *et al.* (1986) 'Mechanism of action of glucocorticosteroids.

- Inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B₄', *Journal of Clinical Investigation*, 77(4), pp. 1244–1250. doi: 10.1172/JCI112427.
- Harapan, H. *et al.* (2020) 'Coronavirus disease 2019 (COVID-19): A literature review', *Journal of Infection and Public Health*, 13(5), pp. 667–673. doi: 10.1016/j.jiph.2020.03.019.
- Harris, J. D. *et al.* (2014) 'How to write a systematic review', *American Journal of Sports Medicine*, 42(11), pp. 2761–2768. doi: 10.1177/0363546513497567.
- Hoogveen, D. *et al.* (2021) 'Effect of high-dose methylprednisolone in mechanically ventilated ICU patients with COVID-19: a retrospective observational study', *Neth j crit care*, 29(2), pp. 91–95. Available at: https://www.njcc.nl/sites/nvic.nl/files/pdf/NJCC_2018-4_Vol.26.pdf#page=14.
- Huang, C. *et al.* (2020) 'Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China', *The Lancet*, 395(10223), pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5.
- Huang, Q. and Wu, X. (2020) 'Targeting inflammation and cytokine storm in COVID-19', *Pharmacological Research*, 159(January).
- Jamaati, H. *et al.* (2021) 'No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial', *European Journal of Pharmacology*, 897, p. 173947. doi: 10.1016/j.ejphar.2021.173947.
- Jeronimo, C. M. P. *et al.* (2021) 'Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial', *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 72(9), pp. e373–e381. doi: 10.1093/cid/ciaa1177.
- Kumar, M. and Al Khodor, S. (2020) 'Pathophysiology and treatment strategies for COVID-19', *Journal of Translational Medicine*, 18(1), pp. 1–9. doi: 10.1186/s12967-020-02520-8.
- Lam, T. T. Y. *et al.* (2020) 'Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins', *Nature*, 583(7815), pp. 282–285. doi: 10.1038/s41586-020-2169-0.
- Landolf, K. M. *et al.* (2021) 'Corticosteroid use in ARDS and its application to evolving therapeutics for coronavirus disease 2019 (COVID-19): A systematic review', *Pharmacotherapy*, 00, pp. 1–20. doi: 10.1002/phar.2637.
- Lee, N. *et al.* (2004) 'Effects of early corticosteroid treatment on plasma

- SARS-associated Coronavirus RNA concentrations in adult patients', *Journal of Clinical Virology*, 31(4), pp. 304–309. doi: 10.1016/j.jcv.2004.07.006.
- Levy, B. D. and Choi, A. M. K. (2013) 'ACUTE RESPIRATORY DISTRESS SYNDROME', in Joseph Loscalzo, Md, P. et al. (eds) *Harrison's Pulmonary and Critical Care Medicine*. 2nd edn. New York: McGraw-Hill Education, pp. 288–294.
- Lin, P. *et al.* (2021) 'Decreased mortality in acute respiratory distress syndrome patients treated with corticosteroids: an updated meta-analysis of randomized clinical trials with trial sequential analysis', *Critical Care*, 25(1), pp. 1–10. doi: 10.1186/s13054-021-03546-0.
- Liu, J. *et al.* (2020) 'Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome', *Journal of Clinical Investigation*, 130(12), pp. 6417–6428. doi: 10.1172/JCI140617.
- Luo, X. *et al.* (2020) 'Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019', *Clinical Infectious Diseases*, 71. doi: 10.1093/cid/ciaa641.
- Madabhavi, I., Sarkar, M. and Kadakol, N. (2020) 'CoviD-19: A review', *Monaldi Archives for Chest Disease*, 90(2), pp. 248–258. doi: 10.4081/monaldi.2020.1298.
- Matthay, M. A. *et al.* (2018) 'Acute respiratory distress syndrome', *Nature Reviews Disease Primers*, 5(1). doi: 10.1038/s41572-019-0069-0.
- Matthay, M. A. *et al.* (2019) 'Acute respiratory distress syndrome', *Nature Reviews Disease Primers*, 5(18). doi: 10.1038/s41572-019-0069-0.
- Matthay, M. A. *et al.* (2020) 'Corticosteroids , COVID-19 pneumonia , and acute respiratory distress syndrome', *The Journal of Clinical Investigation*, 130(12), pp. 6218–6221.
- Matthay, Michael A and Zemans, R. L. (2011) 'The Acute Respiratory Distress Syndrome: Pathogenesis and Treatment', *NIH Public Access*, (6), pp. 147–163. doi: 10.1146/annurev-pathol-011110-130158.The.
- Matthay, Michael A. and Zemans, R. L. (2011) 'The Acute Respiratory Distress Syndrome: Pathogenesis and Treatment', *Annual reviews pathology*, 6, pp. 147–163. doi: 10.1146/annurev-pathol-011110-130158.The.
- Mbuzi, V., Fulbrook, P. and Jessup, M. (2018) 'Effectiveness of programs to promote cardiovascular health of Indigenous Australians: A systematic review', *International Journal for Equity in Health*, 17(1), pp. 1–17. doi: 10.1186/s12939-018-0867-0.
- Meduri, G. U. *et al.* (2007) 'Methylprednisolone Infusion in Early Severe

- ARDS * Results of a Randomized Controlled Trial', *CRITICAL CARE MEDICINE*, 131(4), pp. 954–963. doi: 10.1378/chest.06-2100.
- Mishra, G. P. and Mulani, J. (2020) 'Corticosteroids for COVID-19: the search for an optimum duration of therapy', *The Lancet. Respiratory Medicine*, 9.
- Monedero, P. *et al.* (2021) 'Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study', *Critical Care*, 25(1), pp. 1–13. doi: 10.1186/s13054-020-03422-3.
- Monreal, E. *et al.* (2021) 'High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study', *European Journal of Clinical Microbiology and Infectious Diseases*, 40(4), pp. 761–769. Available at: <https://link.springer.com/content/pdf/10.1007/s10096-020-04078-1.pdf>.
- Neto, A. S. *et al.* (2012) 'Association Between Use of Lung-Protective Ventilation With Lower Tidal Volumes and Clinical Outcomes Among Patients Without Acute Respiratory Distress Syndrome', *JAMA - Journal of the American Medical Association*, 308(16), pp. 1651–1659.
- Nugraha, P. K. *et al.* (2021) 'Comorbidities as Risk Factors for Mortality in COVID-19 Acute Respiratory Distress Syndrome Adult Patients: A Single-Center Retrospective Study', *International Journal of Scientific Advances*, 2(6), pp. 979–984. doi: 10.51542/ijscia.v2i6.10.
- Page, M. J. *et al.* (2021) 'The PRISMA 2020 statement: An updated guideline for reporting systematic reviews', *The BMJ*, 372. doi: 10.1136/bmj.n71.
- Peter Horby *et al.* (2020) 'Dexamethasone in Hospitalized Patients with Covid-19: preliminary report', *New England Journal of Medicine*, 384(8), pp. 693–704. doi: 10.1056/nejmoa2021436.
- Pfortmueller, C. A. *et al.* (2021) 'COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment e A narrative reviewd acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment e A narrati', *Best Practice & Research Clinical Anaesthesiology*, 35(3), pp. 351–368. doi: 10.1016/j.bpa.2020.12.011.
- Ramanathan, K. *et al.* (2020) 'Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding', *The Lancet*, 2020(January), pp. 19–21.
- Rana, M. A. *et al.* (2020) 'Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO₂ / FiO₂ Ratio Among COVID-19 Patients', *Cureus*, 12(10). doi: 10.7759/cureus.10918.
- Ranjbar, K. *et al.* (2021) 'Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial (BMC Infectious

- Diseases, (2021), 21, 1, (337), 10.1186/s12879-021-06', *BMC Infectious Diseases*, 21(1), pp. 1–8. doi: 10.1186/s12879-021-06130-7.
- Saguil, A. and Fargo, M. (2012) 'Acute Respiratory Distress Syndrome: Diagnosis and Management', *American Academy of Family Physicians*, 85(4), pp. 352–358.
- Schimmer, B. P. and Funder, J. W. (2018) 'Adrenocorticotropic Hormone, Adrenal Steroids, and the Adrenal Cortex', in Brunton, L. L., Hilal-Dandan, R., and Knollmann, B. C. (eds) *Goodman and Gilman's*. 13th edn. New York: McGraw-Hill Education, pp. 845–862. doi: 10.4324/9780203813034.
- Soy, M. *et al.* (2020) 'Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment', *Clinical Rheumatology*, 39(7), pp. 2085–2094. doi: 10.1007/s10067-020-05190-5.
- Sterne, J. A. C. *et al.* (2020) 'Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-analysis', *JAMA - Journal of the American Medical Association*, 324(13), pp. 1330–1341. doi: 10.1001/jama.2020.17023.
- Suherman, S. K. and Ascobat, P. (2016) 'Adrenokortikotropin, Adrenokortikosteroid, Analog-sintetik dan Antagonisnya', in Gunawan, S. G. *et al.* (eds) *Farmakologi dan Farmakoterapi*. 6th edn. Jakarta: Badan Penerbit FKUI, pp. 507–527. doi: 10.13140/RG.2.1.4230.4400.
- Susilo, A. *et al.* (2020) 'Coronavirus Disease 2019: Tinjauan Literatur Terkini', *Jurnal Penyakit Dalam Indonesia*, 7(1), p. 45. doi: 10.7454/jpdi.v7i1.415.
- Tang, X. *et al.* (2021) 'Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial', *Respiration*, 100(2), pp. 116–126. doi: 10.1159/000512063.
- Thai, P. *et al.* (2021) 'Factors associated with the duration of hospitalisation among COVID-19 patients in Vietnam: A survival analysis', *Epidemiology and Infection*, 148(e114), pp. 1–7.
- Tomazini, B. M. *et al.* (2020) 'Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial', *JAMA - Journal of the American Medical Association*, 324(13), pp. 1307–1316. doi: 10.1001/jama.2020.17021.
- Tongyoo, S. *et al.* (2016) 'Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: Results of a randomized controlled trial', *Critical Care*, 20(1), pp. 1–11. doi: 10.1186/s13054-016-1511-2.
- Tripathi, K. (2019) 'Corticosteroid', in Tripathi, K. (ed.) *Essentials of Medical Pharmacology*. 8th edn. New Delhi: Jaypee Brother's Medical Publishers,

pp. 306–319.

- Vecchié, A. *et al.* (2021) ‘High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study’, *Internal and Emergency Medicine*, 16(7), pp. 1913–1919. doi: 10.1007/s11739-021-02800-1.
- Villar, J. *et al.* (2020) ‘Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial’, *Lancet Respir Med*, 8, pp. 267–76. doi: 10.1016/S2213-2600(19)30417-5.
- Wang, D. *et al.* (2020) ‘Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China’, *JAMA - Journal of the American Medical Association*, 323(11), pp. 1061–1069. doi: 10.1001/jama.2020.1585.
- Wang, Y. *et al.* (2020) ‘Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures’, *Journal of Medical Virology*, 92(6), pp. 568–576. doi: 10.1002/jmv.25748.
- Warren L. Lee, P. and Arthur S. Slutsky, M. (2016) ‘ACUTE HYPOXEMIC RESPIRATORY FAILURE AND ARDS’, in Broaddus, V. C. *et al.* (eds) *Murray & Nadel’s Textbook of Respiratory Medicine*. 6th edn. Philadelphia: Elsevier, pp. 1740–1760.
- Wiersinga, W. J. *et al.* (2020) ‘Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review’, *JAMA - Journal of the American Medical Association*, 324(8), pp. 782–793. doi: 10.1001/jama.2020.12839.
- Wu, C. *et al.* (2020) ‘Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis’, *Critical Care*, 24(1), pp. 1–10. doi: 10.1186/s13054-020-03340-4.
- Yu, T. *et al.* (2020) ‘Association Between Clinical Manifestations and Prognosis in Patients with COVID-19’, *Clinical Therapeutics*, 42(6), pp. 964–972. doi: 10.1016/j.clinthera.2020.04.009.
- Zulkifli, A. and Johanes, P. (2014) ‘Acute Respiratory Distress Syndrome (ARDS)’, in Setiati, S. *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*. 6th edn. Jakarta Pusat: Interna Publishing, pp. 4072–4079.